User profiles for Riitta Lassila
Riitta LassilaProfessor of Coagulation Medicine, University of Helsinki Verified email at kolumbus.fi Cited by 11706 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
…, S Husted, J Lopez-Sendon, R Lassila… - European heart …, 2011 - academic.oup.com
Aims More intense platelet-directed therapy for acute coronary syndrome (ACS) may increase
bleeding risk. The aim of the current analysis was to determine the rate, clinical impact, …
bleeding risk. The aim of the current analysis was to determine the rate, clinical impact, …
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
VEGF-C is a recently characterised endothelial growth factor structurally related to vascular
endothelial growth factor (VEGF). We studied the expression of VEGF-C and VEGF in the …
endothelial growth factor (VEGF). We studied the expression of VEGF-C and VEGF in the …
European principles of haemophilia care
…, J Astermark, K Fischer, A Gringeri, R Lassila… - …, 2008 - Wiley Online Library
As the management of haemophilia is complex, it is essential that those with the disorder
should have ready access to a range of services provided by a multidisciplinary team of …
should have ready access to a range of services provided by a multidisciplinary team of …
[HTML][HTML] Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors
Background Patients with severe hemophilia A and factor VIII inhibitors are at increased risk
for serious bleeding complications and progression to end-stage joint disease. Effective …
for serious bleeding complications and progression to end-stage joint disease. Effective …
Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity
…, S Vehkavaara, M Syrjälä, R Lassila - … , and vascular biology, 2002 - Am Heart Assoc
Insulin resistance is associated with an increased risk of atherothrombotic vascular disease,
but the mechanisms are poorly understood. We determined how insulin in vivo regulates …
but the mechanisms are poorly understood. We determined how insulin in vivo regulates …
Platelet-derived microparticles associate with fibrin during thrombosis
P Siljander, O Carpen, R Lassila - 1996 - ashpublications.org
Platelet-derived microparticles (MP) are reported to express both pro- and anticoagulant
activities. Nevertheless, their functional significance has remained unresolved. The present …
activities. Nevertheless, their functional significance has remained unresolved. The present …
Obesity‐related derangements of coagulation and fibrinolysis: a study of obesity‐discordant monozygotic twin pairs
…, H Yki‐Järvinen, A Silveira, A Hamsten, R Lassila… - …, 2012 - Wiley Online Library
Coagulation and fibrinolytic activities are under strong genetic control. We studied the effects
of acquired obesity, independent of genetic factors on coagulation and fibrinolysis activities …
of acquired obesity, independent of genetic factors on coagulation and fibrinolysis activities …
No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial
…, K Poussa, S Ilveskero, J Hernesniemi, R Lassila - Journal of …, 2003 - thejns.org
Object. From the moment an intracranial aneurysm ruptures, cerebral blood flow is impaired,
and this impairment mainly determines the outcome in patients who survive after the initial …
and this impairment mainly determines the outcome in patients who survive after the initial …
Increased coagulation factor VIII, IX, XI and XII activities in non‐alcoholic fatty liver disease
…, N Lundbom, A Rissanen, R Lassila… - Liver …, 2011 - Wiley Online Library
Background and aims: Obesity and the metabolic syndrome are established risk factors of
venous thromboembolism. As most coagulation factors are produced exclusively by the liver …
venous thromboembolism. As most coagulation factors are produced exclusively by the liver …
Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients
…, E Kankuri, PJ Karhunen, R Lassila - Thrombosis and …, 2006 - thieme-connect.com
The antiplatelet effect of aspirin varies individually. This study evaluated whether the
antiplatelet effect of aspirin associates with polymorphisms in the genes coding for cyclo-oxygenase…
antiplatelet effect of aspirin associates with polymorphisms in the genes coding for cyclo-oxygenase…